<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 18.5 - Premalignant Disease of the Cervix</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 18.5 - Premalignant Disease of the Cervix | MD3 SCP Cases">
  <meta name="description" content="A 32-year-old with abnormal cervical screening showing high-grade dyskaryosis. Learn about HPV, CIN classification, cervical screening programmes, colposcopy, LLETZ treatment, and the importance of HPV vaccination in preventing cervical cancer.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:url" content="https://md3-scp.netlify.app/cases/case18_5.html">
  <meta property="og:title" content="Case 18.5 - Premalignant Disease of the Cervix">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="A 32-year-old with abnormal cervical screening showing high-grade dyskaryosis. Learn about HPV, CIN classification, cervical screening programmes, colposcopy, LLETZ treatment, and the importance of HPV vaccination in preventing cervical cancer.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">
  <!-- Twitter -->
  <meta property="twitter:card" content="summary">
  <meta property="twitter:title" content="Case 18.5 - Premalignant Disease of the Cervix">
  <meta property="twitter:description" content="A 32-year-old with abnormal cervical screening showing high-grade dyskaryosis. Learn about HPV, CIN classification, cervical screening programmes, colposcopy, LLETZ treatment, and the importance of HPV vaccination in preventing cervical cancer.">
  <meta property="twitter:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">

  <link rel="stylesheet" href="../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 18.5 – Premalignant Disease of the Cervix</h1>
    <p class="meta"><strong>Category:</strong> Medicine | <strong>Discipline:</strong> Obstetrics & Gynaecology | <strong>Setting:</strong> Colposcopy Clinic</p>

    <h2>Case</h2>
    <p>Miss Laura Mitchell, a 32-year-old primary school teacher, attends the colposcopy clinic following an abnormal cervical screening result. Her routine cervical smear (performed 3 weeks ago as part of the NHS Cervical Screening Programme) showed <strong>high-grade dyskaryosis with high-risk HPV (hrHPV) detected</strong>. She was referred urgently to colposcopy.</p>

    <p>Laura is asymptomatic - she has no vaginal bleeding, discharge, or postcoital bleeding. Her periods are regular (28-day cycle) with normal flow. She is sexually active with one regular partner of 5 years and uses the combined oral contraceptive pill for contraception. She has never been pregnant.</p>

    <p>This was her first cervical smear since age 27 (she missed her 25-year invitation due to moving house and forgot to re-register). Her previous smear at age 25 was normal. She did not receive the HPV vaccine as it was not offered to her age cohort (introduced in 2008 for girls aged 12-13).</p>

    <p>She is a non-smoker, drinks alcohol occasionally, and has no significant past medical history. She is anxious about the results and concerned about cancer.</p>

    <div class="vital-signs">
      <strong>At Colposcopy Clinic:</strong>
      <ul>
        <li>General: Appears well, anxious</li>
        <li>Colposcopy findings:
          <ul>
            <li>Transformation zone fully visible (Type 1)</li>
            <li>Application of 5% acetic acid reveals a large <strong>dense acetowhite area</strong> at 6-9 o'clock position covering the posterior lip of the cervix</li>
            <li>Area extends into the endocervical canal</li>
            <li>Irregular surface contour and coarse punctation visible</li>
            <li>Schiller's iodine test: Area does not take up stain (iodine-negative)</li>
            <li>Abnormal vascular patterns noted (mosaicism)</li>
          </ul>
        </li>
        <li>Colposcopic impression: <strong>High-grade CIN (CIN2/3)</strong></li>
        <li>Punch biopsies taken from acetowhite area (x2)</li>
      </ul>
    </div>

    <h2>Investigations</h2>
    <div class="investigation-results">
      <strong>Original Cervical Cytology (GP):</strong>
      <ul>
        <li>Cytology: High-grade dyskaryosis (severe nuclear abnormalities)</li>
        <li>hrHPV test: Positive (HPV 16 detected)</li>
      </ul>
      <strong>Colposcopy-Directed Biopsy (Histology - 2 weeks later):</strong>
      <ul>
        <li><strong>CIN 3 (High-grade squamous intraepithelial lesion - HSIL)</strong></li>
        <li>Full-thickness dysplasia involving the entire epithelium</li>
        <li>No evidence of invasion</li>
        <li>HPV 16 positive</li>
      </ul>
    </div>

    <h2>Questions</h2>

        <div class="question">
      <strong>Question 1: What is the role of HPV in cervical disease, and what is the pathophysiology of cervical intraepithelial neoplasia (CIN)?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>Human Papillomavirus (HPV) and Cervical Disease:</strong></p>

        <p><strong>HPV Overview:</strong></p>
        <ul>
          <li>DNA virus with >200 types, transmitted sexually</li>
          <li>80% of sexually active people will be infected at some point</li>
          <li>Most infections (90%) are cleared by the immune system within 1-2 years</li>
          <li><strong>Persistent high-risk HPV infection</strong> → premalignant changes (CIN) → cervical cancer (if untreated)</li>
        </ul>

        <p><strong>HPV Classification:</strong></p>
        <ul>
          <li><strong>High-risk (oncogenic) types:</strong> HPV 16, 18, 31, 33, 45, 52, 58
            <ul>
              <li><strong>HPV 16</strong> - causes 50-60% of cervical cancers (most common)</li>
              <li><strong>HPV 18</strong> - causes 10-15% (associated with adenocarcinoma)</li>
              <li>Together, HPV 16+18 cause 70% of cervical cancers</li>
            </ul>
          </li>
          <li><strong>Low-risk (non-oncogenic) types:</strong> HPV 6, 11
            <ul>
              <li>Cause genital warts (condylomata acuminata)</li>
              <li>Do NOT cause cancer</li>
            </ul>
          </li>
        </ul>

        <p><strong>Pathophysiology of CIN:</strong></p>
        <ul>
          <li><strong>Transformation zone (T-zone):</strong> Area where columnar epithelium (endocervix) meets squamous epithelium (ectocervix)</li>
          <li>T-zone undergoes <strong>metaplasia</strong> (columnar → squamous) - area vulnerable to HPV infection</li>
          <li><strong>HPV infects basal cells</strong> in T-zone during metaplasia</li>
          <li>HPV produces viral oncoproteins:
            <ul>
              <li><strong>E6</strong> - inactivates p53 (tumour suppressor) → prevents apoptosis</li>
              <li><strong>E7</strong> - inactivates Rb (retinoblastoma protein) → uncontrolled cell division</li>
            </ul>
          </li>
          <li>Result: Dysplasia (abnormal cell growth and maturation) → CIN → invasive cancer (if untreated)</li>
        </ul>

        <p><strong>CIN Classification (Histological):</strong></p>
        <ul>
          <li><strong>CIN 1 (Low-grade):</strong>
            <ul>
              <li>Dysplasia involves lower 1/3 of epithelium</li>
              <li>Mild nuclear abnormalities</li>
              <li>60-80% regress spontaneously (immune clearance of HPV)</li>
              <li>Usually managed conservatively (surveillance, not treatment)</li>
            </ul>
          </li>
          <li><strong>CIN 2 (Moderate/High-grade):</strong>
            <ul>
              <li>Dysplasia involves lower 2/3 of epithelium</li>
              <li>Moderate nuclear abnormalities</li>
              <li>40-60% regress, 20-30% progress to CIN 3, 5% progress to cancer</li>
              <li>Usually treated (especially if age >25)</li>
            </ul>
          </li>
          <li><strong>CIN 3 (High-grade/Severe):</strong>
            <ul>
              <li>Dysplasia involves full thickness of epithelium (but basement membrane intact - NOT invasive)</li>
              <li>Severe nuclear abnormalities, high mitotic activity</li>
              <li>Only 30% regress, 12-30% progress to invasive cancer if untreated (over 10-20 years)</li>
              <li><strong>Requires treatment</strong></li>
            </ul>
          </li>
        </ul>

        <p><strong>Cytology Terms (Smear Results):</strong></p>
        <ul>
          <li><strong>Borderline changes:</strong> Uncertain significance - repeat smear or refer if hrHPV positive</li>
          <li><strong>Low-grade dyskaryosis:</strong> Corresponds to CIN 1</li>
          <li><strong>High-grade dyskaryosis:</strong> Corresponds to CIN 2/3</li>
          <li><strong>? Invasive cancer:</strong> Urgent 2WW referral</li>
        </ul>

        <p><strong>Natural History of CIN:</strong></p>
        <ul>
          <li><strong>Progression timeline:</strong> HPV infection → CIN 1 (1-5 years) → CIN 2/3 (5-10 years) → Invasive cancer (10-20 years)</li>
          <li>NOT all CIN progresses - many lesions (especially CIN 1) regress spontaneously</li>
          <li><strong>Screening detects and treats precancerous changes</strong> → prevents 75% of cervical cancers</li>
        </ul>

        <p><strong>This patient's disease:</strong></p>
        <ul>
          <li>High-risk HPV 16 infection (most oncogenic type)</li>
          <li>CIN 3 (full-thickness dysplasia) - high risk of progression if untreated</li>
          <li>Detected early through screening - curable with treatment</li>
        </ul>
      </div>
    </div>

        <div class="question">
      <strong>Question 2: Explain the UK cervical screening programme and the management of abnormal smears and CIN.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>NHS Cervical Screening Programme (England, 2024):</strong></p>

        <p><strong>Who is screened:</strong></p>
        <ul>
          <li><strong>Age 25-49:</strong> Screened every 3 years</li>
          <li><strong>Age 50-64:</strong> Screened every 5 years</li>
          <li>Programme ends at age 65 (if recent smears normal)</li>
        </ul>

        <p><strong>Why not screen <25 years?</strong></p>
        <ul>
          <li>HPV infection very common in young women (50-80% by age 25)</li>
          <li>Most infections clear spontaneously</li>
          <li>CIN 1 very common, mostly regresses</li>
          <li>Cervical cancer extremely rare <25 years</li>
          <li>Screening would cause overtreatment, anxiety, and cervical trauma (risk of preterm birth)</li>
        </ul>

        <p><strong>HPV Primary Screening (since 2019):</strong></p>
        <ul>
          <li>All samples tested for <strong>high-risk HPV (hrHPV) first</strong></li>
          <li><strong>If hrHPV negative:</strong> Return to routine recall (no cytology needed) - very low risk</li>
          <li><strong>If hrHPV positive:</strong> Sample undergoes cytology (liquid-based cytology - LBC)</li>
        </ul>

        <p><strong>Management of Abnormal Smears (NHS Pathway):</strong></p>

        <table border="1" cellpadding="5" style="width:100%; border-collapse: collapse; margin-top: 10px;">
          <tr>
            <th>Result</th>
            <th>Management</th>
          </tr>
          <tr>
            <td>hrHPV negative</td>
            <td>Routine recall (3 or 5 years)</td>
          </tr>
          <tr>
            <td>hrHPV positive + Normal cytology</td>
            <td>Repeat in 12 months (test of cure)</td>
          </tr>
          <tr>
            <td>hrHPV positive + Borderline/Low-grade dyskaryosis</td>
            <td>Repeat in 12 months. If persistent at 12m → colposcopy</td>
          </tr>
          <tr>
            <td>hrHPV positive + High-grade dyskaryosis</td>
            <td><strong>Urgent colposcopy</strong> (within 6 weeks)</td>
          </tr>
          <tr>
            <td>? Invasive cancer/Glandular neoplasia</td>
            <td><strong>Urgent 2WW colposcopy</strong> (within 2 weeks)</td>
          </tr>
        </table>

        <p><strong>Colposcopy:</strong></p>
        <ul>
          <li><strong>Definition:</strong> Examination of cervix using colposcope (magnifying microscope)</li>
          <li><strong>Procedure:</strong>
            <ul>
              <li>5% acetic acid applied → abnormal cells turn white ("acetowhite")</li>
              <li>Lugol's iodine (Schiller's test) → normal cells stain brown, abnormal cells do not</li>
              <li>Abnormal vascular patterns assessed (punctation, mosaicism)</li>
              <li><strong>Punch biopsies</strong> taken from abnormal areas for histology</li>
            </ul>
          </li>
          <li><strong>Colposcopic features of high-grade CIN:</strong>
            <ul>
              <li>Dense acetowhite changes</li>
              <li>Coarse punctation/mosaicism</li>
              <li>Irregular surface contour</li>
              <li>Iodine-negative (does not take up stain)</li>
            </ul>
          </li>
        </ul>

        <p><strong>Treatment of CIN:</strong></p>

        <p><strong>Conservative Management (CIN 1 in women <25):</strong></p>
        <ul>
          <li>Observation with repeat cytology/colposcopy at 6-12 months</li>
          <li>High regression rate (60-80%)</li>
          <li>Treatment only if persistent >2 years or progression</li>
        </ul>

        <p><strong>Excisional Treatment (CIN 2/3):</strong></p>
        <ul>
          <li><strong>LLETZ (Large Loop Excision of Transformation Zone)</strong>
            <ul>
              <li><strong>First-line treatment</strong> for CIN 2/3</li>
              <li>Performed under local anaesthetic (can be done at first colposcopy - "See and Treat")</li>
              <li>Diathermy wire loop removes abnormal tissue from transformation zone</li>
              <li>Specimen sent for histology (confirms CIN grade, excludes invasion, checks margins)</li>
              <li>95-98% cure rate</li>
              <li><strong>Complications:</strong> Bleeding (immediate/delayed), infection, cervical stenosis, slight increased risk of preterm birth in future pregnancies</li>
            </ul>
          </li>
          <li><strong>Cone biopsy (Cold knife/Laser):</strong>
            <ul>
              <li>Larger excision if disease extends into endocervical canal</li>
              <li>Usually under GA</li>
              <li>Higher risk of preterm birth than LLETZ</li>
            </ul>
          </li>
        </ul>

        <p><strong>Ablative Treatment (alternative):</strong></p>
        <ul>
          <li>Cryotherapy or laser ablation - destroys tissue (no specimen for histology)</li>
          <li>Less commonly used than LLETZ in UK</li>
        </ul>

        <p><strong>Follow-up After Treatment (Test of Cure):</strong></p>
        <ul>
          <li><strong>hrHPV test + cytology at 6 months post-treatment</strong>
            <ul>
              <li>If hrHPV negative: Return to routine screening (but recall at 3 years, not 5)</li>
              <li>If hrHPV positive: Repeat at 12 months or refer back to colposcopy</li>
            </ul>
          </li>
          <li>Annual surveillance for 10 years (increased recall)</li>
        </ul>

        <p><strong>HPV Vaccination (Prevention):</strong></p>
        <ul>
          <li><strong>Gardasil 9 (current UK vaccine):</strong> Protects against HPV 16, 18, 31, 33, 45, 52, 58 + HPV 6, 11 (warts)</li>
          <li><strong>Coverage:</strong> Prevents 90% of cervical cancers</li>
          <li><strong>UK programme:</strong> Offered to all children aged 12-13 (boys and girls since 2019)</li>
          <li>Also available up to age 25 (catch-up programme)</li>
          <li><strong>Note:</strong> Vaccination does NOT replace screening - vaccinated individuals still need smears</li>
        </ul>

        <p><strong>This patient's management:</strong></p>
        <ol>
          <li><strong>Diagnosis confirmed:</strong> CIN 3 on colposcopy-directed biopsy</li>
          <li><strong>Treatment:</strong> LLETZ performed (See and Treat at colposcopy or planned procedure)
            <ul>
              <li>Excision of transformation zone under local anaesthetic</li>
              <li>Histology confirms complete excision with clear margins</li>
            </ul>
          </li>
          <li><strong>Follow-up (Test of Cure):</strong>
            <ul>
              <li>hrHPV test + cytology at 6 months post-LLETZ</li>
              <li>If hrHPV negative → routine recall (3-yearly for 10 years)</li>
              <li>If hrHPV positive or cytology abnormal → repeat colposcopy</li>
            </ul>
          </li>
          <li><strong>Prognosis:</strong> Excellent - >95% cure rate with LLETZ. No progression to cancer if treated appropriately</li>
          <li><strong>Counselling:</strong>
            <ul>
              <li>Reassure CIN is NOT cancer - it is precancerous and highly treatable</li>
              <li>Explain slight increased risk of preterm birth in future pregnancies (cervical weakness)</li>
              <li>HPV is common, sexually transmitted, but most infections clear spontaneously</li>
            </ul>
          </li>
        </ol>
      </div>
    </div>

    <h2>Key Learning Points</h2>
    <div class="key-points">
      <ul>
        <li><strong>HPV 16 and 18</strong> cause 70% of cervical cancers. Persistent high-risk HPV infection → CIN → cancer (if untreated)</li>
        <li><strong>CIN</strong> (Cervical Intraepithelial Neoplasia) = dysplasia of cervical epithelium. CIN 1 (lower 1/3), CIN 2 (lower 2/3), CIN 3 (full thickness)</li>
        <li><strong>UK screening:</strong> Age 25-49 every 3 years, age 50-64 every 5 years. <strong>HPV primary screening</strong> - hrHPV test first, then cytology if positive</li>
        <li><strong>High-grade dyskaryosis (CIN 2/3)</strong> → urgent colposcopy (6 weeks)</li>
        <li><strong>Colposcopy:</strong> Acetic acid (acetowhite changes), iodine (Schiller's test), punch biopsies for histology</li>
        <li><strong>Treatment: LLETZ (Large Loop Excision)</strong> - first-line for CIN 2/3, 95-98% cure rate, local anaesthetic, slight preterm birth risk</li>
        <li><strong>Test of Cure:</strong> hrHPV + cytology at 6 months post-treatment. If negative → routine recall (3-yearly)</li>
        <li><strong>CIN 1</strong> usually observed (high regression rate), especially in women <25</li>
        <li><strong>HPV vaccination (Gardasil 9)</strong> prevents 90% of cervical cancers - offered to all 12-13 year olds (boys + girls)</li>
        <li><strong>Screening saves lives:</strong> Detects precancerous changes early → treatment prevents 75% of cervical cancers</li>
        <li><strong>CIN is NOT cancer</strong> - it is premalignant and highly curable with treatment</li>
      </ul>
    </div>

  </div>

  <!-- JavaScript -->  <script src="../js/firebase-config.js"></script>
  <script src="../js/auth.js"></script>
  <script src="../js/completion-tracker.js"></script>
  <script src="../js/flag-tracker.js"></script>
  <script src="../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        }
      }
    }// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          }
        }, 100);
      }
    });
    }
  </script>

</body>
</html>
